Pharmacokinetics of Clindamycin in the Plasma and Dialysate after Intraperitoneal Administration of Clindamycin Phosphoester to Patients on Continuous Ambulatory Peritoneal Dialysis

An Open-Label, Prospective, Single-Dose, Two-Institution Study

Min Jung Chang, Hyunguk Namgung, Hye D. Choi, Young R. Song, Sung G. Kim, Jung M. Oh, Wan G. Shin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We evaluated the pharmacokinetics of clindamycin and the dose of clindamycin phosphate necessary to treat peritonitis after intraperitoneal administration of clindamycin phosphate to patients on continuous ambulatory peritoneal dialysis (CAPD). This was an open-label, prospective, single-dose study conducted at the two levels of institutional clinical care in South Korea. Twelve patients (six men and six women; all older than 25years), mean CAPD duration of 38.2months with various origins without peritonitis, received 600mg clindamycin phosphate mixed with only the first 2-L dialysate (1.5% dextrose). The 1.5%, 1.5%, 2.5% and 1.5% dextrose dialysates were serially exchanged every 6hr. If patients were non-anuric, 24-hr urine samples were also collected. Clindamycin phosphate was incompletely activated to clindamycin in the dialysate. The clindamycin concentration in the dialysate was greater than the effective concentration (5μg/mL) at 6.87μg/mL up to 6hr. So, 600mg clindamycin phosphate per every 6hr dialysate is effective for treatment of peritonitis. It has been reported that the clindamycin concentrations in the dialysate may be higher in CAPD patients with peritonitis. Thus, we can expect that intraperitoneal administration of <600mg clindamycin phosphate per every 6hr dialysate could be maintained over 5μg/mL in patients with peritonitis. The transfer of clindamycin was unidirectional from the dialysate to the plasma.

Original languageEnglish
Pages (from-to)504-509
Number of pages6
JournalBasic and Clinical Pharmacology and Toxicology
Volume110
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Pharmacokinetics
Dialysis
Continuous Ambulatory Peritoneal Dialysis
Clindamycin
Dialysis Solutions
Labels
Plasmas
Peritonitis
Glucose
Republic of Korea
clindamycin phosphate
Urine

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology

Cite this

@article{60f0bc56afc0461da5623760a109ef31,
title = "Pharmacokinetics of Clindamycin in the Plasma and Dialysate after Intraperitoneal Administration of Clindamycin Phosphoester to Patients on Continuous Ambulatory Peritoneal Dialysis: An Open-Label, Prospective, Single-Dose, Two-Institution Study",
abstract = "We evaluated the pharmacokinetics of clindamycin and the dose of clindamycin phosphate necessary to treat peritonitis after intraperitoneal administration of clindamycin phosphate to patients on continuous ambulatory peritoneal dialysis (CAPD). This was an open-label, prospective, single-dose study conducted at the two levels of institutional clinical care in South Korea. Twelve patients (six men and six women; all older than 25years), mean CAPD duration of 38.2months with various origins without peritonitis, received 600mg clindamycin phosphate mixed with only the first 2-L dialysate (1.5{\%} dextrose). The 1.5{\%}, 1.5{\%}, 2.5{\%} and 1.5{\%} dextrose dialysates were serially exchanged every 6hr. If patients were non-anuric, 24-hr urine samples were also collected. Clindamycin phosphate was incompletely activated to clindamycin in the dialysate. The clindamycin concentration in the dialysate was greater than the effective concentration (5μg/mL) at 6.87μg/mL up to 6hr. So, 600mg clindamycin phosphate per every 6hr dialysate is effective for treatment of peritonitis. It has been reported that the clindamycin concentrations in the dialysate may be higher in CAPD patients with peritonitis. Thus, we can expect that intraperitoneal administration of <600mg clindamycin phosphate per every 6hr dialysate could be maintained over 5μg/mL in patients with peritonitis. The transfer of clindamycin was unidirectional from the dialysate to the plasma.",
author = "Chang, {Min Jung} and Hyunguk Namgung and Choi, {Hye D.} and Song, {Young R.} and Kim, {Sung G.} and Oh, {Jung M.} and Shin, {Wan G.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1111/j.1742-7843.2011.00842.x",
language = "English",
volume = "110",
pages = "504--509",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics of Clindamycin in the Plasma and Dialysate after Intraperitoneal Administration of Clindamycin Phosphoester to Patients on Continuous Ambulatory Peritoneal Dialysis

T2 - An Open-Label, Prospective, Single-Dose, Two-Institution Study

AU - Chang, Min Jung

AU - Namgung, Hyunguk

AU - Choi, Hye D.

AU - Song, Young R.

AU - Kim, Sung G.

AU - Oh, Jung M.

AU - Shin, Wan G.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - We evaluated the pharmacokinetics of clindamycin and the dose of clindamycin phosphate necessary to treat peritonitis after intraperitoneal administration of clindamycin phosphate to patients on continuous ambulatory peritoneal dialysis (CAPD). This was an open-label, prospective, single-dose study conducted at the two levels of institutional clinical care in South Korea. Twelve patients (six men and six women; all older than 25years), mean CAPD duration of 38.2months with various origins without peritonitis, received 600mg clindamycin phosphate mixed with only the first 2-L dialysate (1.5% dextrose). The 1.5%, 1.5%, 2.5% and 1.5% dextrose dialysates were serially exchanged every 6hr. If patients were non-anuric, 24-hr urine samples were also collected. Clindamycin phosphate was incompletely activated to clindamycin in the dialysate. The clindamycin concentration in the dialysate was greater than the effective concentration (5μg/mL) at 6.87μg/mL up to 6hr. So, 600mg clindamycin phosphate per every 6hr dialysate is effective for treatment of peritonitis. It has been reported that the clindamycin concentrations in the dialysate may be higher in CAPD patients with peritonitis. Thus, we can expect that intraperitoneal administration of <600mg clindamycin phosphate per every 6hr dialysate could be maintained over 5μg/mL in patients with peritonitis. The transfer of clindamycin was unidirectional from the dialysate to the plasma.

AB - We evaluated the pharmacokinetics of clindamycin and the dose of clindamycin phosphate necessary to treat peritonitis after intraperitoneal administration of clindamycin phosphate to patients on continuous ambulatory peritoneal dialysis (CAPD). This was an open-label, prospective, single-dose study conducted at the two levels of institutional clinical care in South Korea. Twelve patients (six men and six women; all older than 25years), mean CAPD duration of 38.2months with various origins without peritonitis, received 600mg clindamycin phosphate mixed with only the first 2-L dialysate (1.5% dextrose). The 1.5%, 1.5%, 2.5% and 1.5% dextrose dialysates were serially exchanged every 6hr. If patients were non-anuric, 24-hr urine samples were also collected. Clindamycin phosphate was incompletely activated to clindamycin in the dialysate. The clindamycin concentration in the dialysate was greater than the effective concentration (5μg/mL) at 6.87μg/mL up to 6hr. So, 600mg clindamycin phosphate per every 6hr dialysate is effective for treatment of peritonitis. It has been reported that the clindamycin concentrations in the dialysate may be higher in CAPD patients with peritonitis. Thus, we can expect that intraperitoneal administration of <600mg clindamycin phosphate per every 6hr dialysate could be maintained over 5μg/mL in patients with peritonitis. The transfer of clindamycin was unidirectional from the dialysate to the plasma.

UR - http://www.scopus.com/inward/record.url?scp=84862790034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862790034&partnerID=8YFLogxK

U2 - 10.1111/j.1742-7843.2011.00842.x

DO - 10.1111/j.1742-7843.2011.00842.x

M3 - Article

VL - 110

SP - 504

EP - 509

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 6

ER -